TOP > 外国特許検索 > METHOD FOR PREPARING ENANTIOMER OF SULFOXIDE COMPOUND, AND SYSTEM FOR PREPARING ENANTIOMER

METHOD FOR PREPARING ENANTIOMER OF SULFOXIDE COMPOUND, AND SYSTEM FOR PREPARING ENANTIOMER 新技術説明会

外国特許コード F210010385
整理番号 (T2019-034,S2019-0388-N0)
掲載日 2021年5月6日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2020JP032053
国際公開番号 WO 2021039800
国際出願日 令和2年8月25日(2020.8.25)
国際公開日 令和3年3月4日(2021.3.4)
優先権データ
  • 特願2019-156444 (2019.8.29) JP
発明の名称 (英語) METHOD FOR PREPARING ENANTIOMER OF SULFOXIDE COMPOUND, AND SYSTEM FOR PREPARING ENANTIOMER 新技術説明会
発明の概要(英語) Provided is an enantiomer preparation method in which one enantiomer of a sulfoxide compound is selectively prepared, the sulfoxide compound having a sulfur atom of a sulfoxide group as an asymmetric center, and the method comprising: a step A for optically resolving an enantiomer mixture of a sulfoxide compound into one enantiomer and the other enantiomer; a step B for irradiating with light the other enantiomer obtained in step A or step C to racemize the enantiomer; and step C for optically resolving the enantiomer mixture of the sulfoxide compound obtained in step B into one enantiomer and the other enantiomer. Also provided is a system for preparing an enantiomer, the system being used in the enantiomer preparation method.
従来技術、競合技術の概要(英語) BACKGROUND ART
Sulfoxide compounds such as omeprazole and lansoprazole have been known as proton pump inhibitors. These sulfoxide compounds have an asymmetric center at the sulfur atom of the sulfoxide group, and the S enantiomer and the R enantiomer exist based on the stereoconfiguration of the asymmetric center.
Sulfoxide compounds described above are known to differ in pharmacokinetics and the like between enantiomers. For example, esomeprazole, which is the S form of omeprazole, is known to exhibit smaller interindividual variations in pharmacokinetics and pharmacological effects than the racemic form of omeprazole. Furthermore, dexlansoprazole, which is the R form of lansoprazole, is known to have superior stability with respect to pharmacometabolic enzymes and pharmacokinetics compared to lansoprazole, which is the racemic form.
From such background, various methods for efficiently obtaining a desired enantiomer from a sulfoxide compound that is a racemic form have been proposed (for example, see Patent Document 1 ~ 3).
However, since the sulfoxide compound, which is a racemic form, is an equivalent mixture of the S form and the R form, in the method described in Patent Document 1 ~ 3, the desired enantiomer can be obtained only in a yield of 50 % at most, and the remaining enantiomer is wasted.
On the other hand, optically active sulfoxide compounds have been reported to undergo racemization (photoracemization) by photoirradiation (see NpL 1 and NpL 2, for example).
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • TOKYO UNIVERSITY OF SCIENCE FOUNDATION
  • 発明者(英語)
  • TAKAHASHI Hideyo
  • MAKINO Kosho
  • GU Kaya
  • TANAKA Yuki
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS IT JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN WS ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
上記の特許・技術に関心のある方は、下記問合せ先にご相談下さい。

PAGE TOP

close
close
close
close
close
close